Table 1.
Patient characteristics
| Arm A (single dosing) | Arm B (daily dosing) | |
| Number of patients | 40 | 40 |
| Male/female (N) | 30/10 | 30/10 |
| Median age (range), years | 62 (27–82) | 58 (27–81) |
| ECOG ≥2 | 16 (40) | 11 (27.5) |
| Diagnosis | ||
| Diffuse large B-cell lymphoma | 27 (67.5) | 23 (57.5) |
| Mantle cell lymphoma | 7 (17.5) | 9 (22.5) |
| Burkitt’s lymphoma | 1 (2.5) | 2 (5) |
| Others | 5 (12.5) | 6 (15) |
| Risk for TLS | ||
| High risk | 21 (51.5) | 19 (47.5) |
| Potential | 19 (47.5) | 21 (51.5) |
| Baseline plasma uric acid | ||
| >7.5 mg/dl | 15 (38) | 14 (35) |
| ≤7.5 mg/dl | 25 (62) | 26 (65) |
| Baseline LDH > 2× ULN | 11 (27.5) | 12 (30) |
| Baseline creatinine elevated (>ULN) | 10 (25) | 6 (15) |
| Spontaneous TLSa | ||
| Laboratory TLS | 5 (12.5) | 1 (2.5) |
| Anthracyclin-based chemotherapy | 37 (92.5) | 35 (87.5) |
Values are given as N (%) unless stated otherwise.
a
Presence of tumor lysis syndrome before initiating chemotherapy.
ECOG, Eastern Cooperative Oncology Group; TLS, tumor lysis syndrome; LDH, lactate dehydrogenase; ULN, upper limit of normal.